AR107500A1 - Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios - Google Patents
Terapia de combinación de inhibidores de bromodominio y moduladores inmunitariosInfo
- Publication number
- AR107500A1 AR107500A1 ARP160103015A ARP160103015A AR107500A1 AR 107500 A1 AR107500 A1 AR 107500A1 AR P160103015 A ARP160103015 A AR P160103015A AR P160103015 A ARP160103015 A AR P160103015A AR 107500 A1 AR107500 A1 AR 107500A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- bromodomain inhibitor
- immune
- tautomer
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
La presente divulga un método para tratar el cáncer en un sujeto que necesita el mismo, comprendiendo el método administrar al sujeto una cantidad terapéuticamente eficaz de un inhibidor de bromodominio; y, un modulador inmunitario. Reivindicación 11: El método de la reivindicación 9 ó 10, donde el inhibidor de bromodominio es JQ1 de fórmula (1), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 12: El método de la reivindicación 9 ó 10, donde el inhibidor de bromodominio es Y803 de fórmula (2), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 13: El método de la reivindicación 9 ó 10, donde el inhibidor de bromodominio es CPI-203 de fórmula (3), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 14: El método de una cualquiera de las reivindicaciones 1 a 8, donde el inhibidor de bromodominio es dBET1 de fórmula (4) o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 17: El método de la reivindicación 15 ó 16, donde el inhibidor de bromodominio es IBET-151 de fórmula (5), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 20: El método de la reivindicación 18 ó 19, donde el inhibidor de bromodominio es IBET-762 de fórmula (6), o una sal, solvato, hidrato, polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 23: El método de la reivindicación 21 ó 22, donde el inhibidor de bromodominio es RVX-208 de fórmula (7), o una sal, solvato, hidrato polimorfo, co-cristal, tautómero, estereoisómero, derivado marcado con isótopos o profármaco farmacéuticamente aceptable del mismo. Reivindicación 37: El método de la reivindicación 36, donde la molécula inmunitaria estimuladora se selecciona entre el grupo que consiste en 4-1BB (CD137), CD137L, OX40, OX40L, ICOS, CD40, CD40L, CD70, CD27, CD28, CD80, CD86, B7RP1 y HVEM. Reivindicación 38: El método de una cualquiera de las reivindicaciones 1 a 35, donde el modulador inmunitario es un inhibidor de puntos de control inmunitarios. Reivindicación 39: El método de la reivindicación 39, donde el inhibidor de puntos de control inmunitarios es un inhibidor de una proteína de puntos de control inmunitarios seleccionada entre el grupo que consiste en: CTLA-4, PD-1, PDL-1, TIM3, LAG3, B7-H3, B7-H4, BTLA, GAL9 y A2aR. Reivindicación 49: El método de la reivindicación 39, donde el inhibidor de puntos de control inmunitarios es un inhibidor de A2aR. Reivindicación 50: El método de la reivindicación 49, donde el modulador inmunitario es un péptido, anticuerpo, ARN de interferencia, o molécula pequeña. Reivindicación 51: El método de la reivindicación 50, donde el modulador inmunitario es un anticuerpo monoclonal, o una proteína de fusión de Ig. Reivindicación 52: El método de la reivindicación 51, donde el modulador inmunitario es un anticuerpo anti-4-1BB. Reivindicación 53: El método de la reivindicación 51, donde el modulador inmunitario es un anticuerpo anti-PD-1. Reivindicación 54: El método de una cualquiera de las reivindicaciones 1 a 53, donde el inhibidor de bromodominio y el modulador inmunitario se administran al sujeto simultáneamente como una única composición. Reivindicación 60: El método de una cualquiera de las reivindicaciones 1 a 59, donde el inhibidor de bromodominio y el modulador inmunitario son sinérgicos en el tratamiento del cáncer, en comparación con el inhibidor de bromodominio en solitario o el modulador inmunitario en solitario.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236280P | 2015-10-02 | 2015-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107500A1 true AR107500A1 (es) | 2018-05-09 |
Family
ID=57137298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103015A AR107500A1 (es) | 2015-10-02 | 2016-09-30 | Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190192532A1 (es) |
| EP (1) | EP3355922A2 (es) |
| JP (1) | JP2018530554A (es) |
| KR (1) | KR20180081507A (es) |
| CN (1) | CN108289957A (es) |
| AR (1) | AR107500A1 (es) |
| AU (1) | AU2016331190A1 (es) |
| BR (1) | BR112018006689A2 (es) |
| CA (1) | CA2999523A1 (es) |
| CL (1) | CL2018000853A1 (es) |
| HK (1) | HK1256269A1 (es) |
| IL (1) | IL258212A (es) |
| MA (1) | MA43037A (es) |
| MX (1) | MX2018003824A (es) |
| PE (1) | PE20181068A1 (es) |
| WO (1) | WO2017059319A2 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1907000T5 (pl) * | 2005-06-08 | 2020-11-16 | Dana-Farber Cancer Institute | Metody i kompozycje do leczenia infekcji przetrwałych |
| KR20170078862A (ko) | 2008-05-16 | 2017-07-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
| CA2735522C (en) | 2008-08-28 | 2017-04-18 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| BR112012029005A2 (pt) | 2010-05-14 | 2016-07-26 | Dana Farber Cancer Inst Inc | composições e métodos de tratamento de neoplasia, doença inflamatória e outros distúrbios |
| SG11201500429QA (en) | 2012-07-20 | 2015-03-30 | Taiga Biotechnologies Inc | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| US10925881B2 (en) | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| SG11201703414VA (en) | 2014-10-27 | 2017-05-30 | Tensha Therapeutics Inc | Bromodomain inhibitors |
| WO2017205721A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| IL293611A (en) | 2016-12-02 | 2022-08-01 | Taiga Biotechnologies Inc | Nanoparticle formulations |
| CN109232440B (zh) * | 2018-01-16 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
| WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| JP2022516401A (ja) | 2018-11-30 | 2022-02-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN109666723B (zh) * | 2019-01-22 | 2022-04-15 | 南通大学 | 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用 |
| EP3969041A4 (en) * | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| US20230093080A1 (en) * | 2019-07-15 | 2023-03-23 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP4067352A4 (en) * | 2019-11-26 | 2023-11-29 | Benobio Co., Ltd. | NOVEL QUERCETIN REDUCTION DERIVATIVE AND ITS USE AS A BET INHIBITOR |
| BR112022011651A2 (pt) | 2019-12-17 | 2022-08-23 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2652304T3 (es) * | 2009-11-05 | 2018-02-01 | Glaxosmithkline Llc | Compuesto de benzodiacepina novedoso |
| CN103180318B (zh) * | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| BR112012029005A2 (pt) * | 2010-05-14 | 2016-07-26 | Dana Farber Cancer Inst Inc | composições e métodos de tratamento de neoplasia, doença inflamatória e outros distúrbios |
| US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| CA2901799A1 (en) * | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases |
| US20150376196A1 (en) * | 2013-02-22 | 2015-12-31 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| JP2016519672A (ja) * | 2013-03-15 | 2016-07-07 | ジェネンテック， インコーポレイテッド | ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| EP3030242A1 (en) * | 2013-08-06 | 2016-06-15 | Oncoethix GmbH | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| CA2926946A1 (en) * | 2013-10-11 | 2015-04-16 | Genentech, Inc. | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy |
| AR099379A1 (es) * | 2013-12-24 | 2016-07-20 | Bristol Myers Squibb Co | Compuestos tricíclicos como agentes antineoplásicos |
-
2016
- 2016-09-30 CA CA2999523A patent/CA2999523A1/en not_active Abandoned
- 2016-09-30 WO PCT/US2016/054924 patent/WO2017059319A2/en active Application Filing
- 2016-09-30 KR KR1020187012018A patent/KR20180081507A/ko unknown
- 2016-09-30 CN CN201680070462.8A patent/CN108289957A/zh active Pending
- 2016-09-30 MX MX2018003824A patent/MX2018003824A/es unknown
- 2016-09-30 EP EP16781957.2A patent/EP3355922A2/en not_active Withdrawn
- 2016-09-30 US US15/764,131 patent/US20190192532A1/en not_active Abandoned
- 2016-09-30 JP JP2018517255A patent/JP2018530554A/ja active Pending
- 2016-09-30 BR BR112018006689A patent/BR112018006689A2/pt not_active IP Right Cessation
- 2016-09-30 PE PE2018000491A patent/PE20181068A1/es unknown
- 2016-09-30 AR ARP160103015A patent/AR107500A1/es unknown
- 2016-09-30 AU AU2016331190A patent/AU2016331190A1/en not_active Abandoned
- 2016-09-30 MA MA043037A patent/MA43037A/fr unknown
-
2018
- 2018-03-19 IL IL258212A patent/IL258212A/en unknown
- 2018-04-02 CL CL2018000853A patent/CL2018000853A1/es unknown
- 2018-11-29 HK HK18115329.0A patent/HK1256269A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108289957A (zh) | 2018-07-17 |
| CA2999523A1 (en) | 2017-04-06 |
| EP3355922A2 (en) | 2018-08-08 |
| CL2018000853A1 (es) | 2018-08-31 |
| JP2018530554A (ja) | 2018-10-18 |
| MA43037A (fr) | 2018-08-08 |
| KR20180081507A (ko) | 2018-07-16 |
| MX2018003824A (es) | 2019-04-01 |
| WO2017059319A2 (en) | 2017-04-06 |
| BR112018006689A2 (pt) | 2018-10-09 |
| WO2017059319A3 (en) | 2017-10-12 |
| PE20181068A1 (es) | 2018-07-04 |
| IL258212A (en) | 2018-05-31 |
| AU2016331190A1 (en) | 2018-04-12 |
| US20190192532A1 (en) | 2019-06-27 |
| HK1256269A1 (zh) | 2019-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107500A1 (es) | Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios | |
| JP2018530554A5 (es) | ||
| JP2020514363A5 (es) | ||
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| MY198034A (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| US20230042913A1 (en) | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof | |
| MX2020005894A (es) | Composicion combinada de un anticuerpo anti-pd-1 y lcl161 para el tratamiento de cancer. | |
| CL2019003000A1 (es) | Proteínas de unión a antígenos trem2 y usos de estas. | |
| CN111163798A (zh) | 用于抗lag-3抗体的给药方案及其用途 | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| JP2019513725A5 (es) | ||
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| MX2021007497A (es) | Anticuerpos biespecificos anti-cd28 x anti-cd22 y usos de estos. | |
| PH12018501877A1 (en) | Substituted indole mcl-1 inhibitors | |
| JP2019530431A5 (es) | ||
| RU2017112379A (ru) | Сочетанные способы лечения с использованием ингибиторов alk | |
| MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
| JP2020502147A5 (es) | ||
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| CA3176246A1 (en) | Antibodies to tigit | |
| CA3058262A1 (en) | Chimeric polypeptides and methods of altering the membrane localization of the same | |
| US20220227876A1 (en) | Rank antagonists and uses thereof | |
| JP2023525423A (ja) | Ｐｒａｍｅに特異的に結合する抗原結合タンパク質 | |
| CA3234647A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination therapy | |
| WO2022147222A1 (en) | Antibodies to tnfr2 and uses thereof |